Vor Biopharma Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$371.6M | -$121.2M | -$126.0M | -$93.4M | -$69.0M |
| Operating expenses | $371.6M | $121.2M | $126.0M | $93.4M | $69.0M |
| Cash from operations | -$142.7M | -$99.7M | -$100.3M | -$85.1M | -$69.1M |
| Capital expenditure | $941,000 | $229,000 | $1.1M | $8.5M | $3.9M |
| Free cash flow | -$143.7M | -$99.9M | -$101.4M | -$93.6M | -$73.0M |
| Impairments | $0 | $0 | $0 | $0 | — |
| Total assets | $464.1M | $142.9M | $198.1M | $299.4M | $242.6M |
| Total liabilities | $628.4M | $46.2M | $47.4M | $48.8M | $26.3M |
Shares outstanding 54.2M · Free float 90.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.